The U.S. government is launching a demonstration program to make obesity drugs, such as GLP-1 receptor agonists, available to Medicare beneficiaries for the first time. This initiative, named the Bridge program, circumvents the statutory ban on Medicare coverage for obesity treatments by utilizing a temporary coverage model. The move follows resistance from private insurers regarding a previously proposed voluntary coverage structure.